1. Emerging Moxifloxacin Resistance in Pseudomonas aeruginosa Keratitis Isolates in South India
- Author
-
Oldenburg, Catherine E, Lalitha, Prajna, Srinivasan, Muthiah, Rajaraman, Revathi, Ravindran, Meenakshi, Mascarenhas, Jeena, Borkar, Durga S, Ray, Kathryn J, Zegans, Michael E, McLeod, Stephen D, Porco, Travis C, Lietman, Thomas M, and Acharya, Nisha R
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Ophthalmology and Optometry ,Clinical Trials and Supportive Activities ,Eye Disease and Disorders of Vision ,Clinical Research ,Rare Diseases ,Antimicrobial Resistance ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Anti-Bacterial Agents ,Aza Compounds ,Communicable Diseases ,Emerging ,Cornea ,Corneal Ulcer ,Double-Blind Method ,Drug Resistance ,Bacterial ,Drug Therapy ,Combination ,Eye Infections ,Bacterial ,Fluoroquinolones ,Glucocorticoids ,Humans ,India ,Microbial Sensitivity Tests ,Moxifloxacin ,Prednisolone ,Pseudomonas Infections ,Pseudomonas aeruginosa ,Quinolines ,Antibiotic resistance ,corneal ulcer ,fluoroquinolones ,infection ,Pseudomonas ,Clinical Sciences ,Opthalmology and Optometry ,Public Health and Health Services ,Epidemiology ,Ophthalmology and optometry ,Public health - Abstract
PurposeTo describe temporal trends in Pseudomonas aeruginosa resistance to moxifloxacin in keratitis isolates from South India.MethodsThe Steroids for Corneal Ulcers Trial (SCUT) was a randomized, double-masked, placebo-controlled trial assessing outcomes in patients with culture positive bacterial corneal ulcers randomized to receive prednisolone phosphate or placebo. All patients received moxifloxacin, and susceptibility to moxifloxacin was measured at baseline using Etest. We investigated trends in moxifloxacin susceptibility of P. aeruginosa during 2007, 2008, and 2009 isolated in SCUT in South India.ResultsThere were 89 P. aeruginosa isolates during 2007, 2008, and 2009 in SCUT that were eligible for this study. There was an increase in the proportion of resistant isolates from 19% in 2007 to 52% in 2009 (p = 0.02, χ(2) test for trend). Logistic regression showed that there was a 2-fold increase in odds of resistance per 1 year increase during the study period (odds ratio 2.16, 95% confidence interval 1.09-4.26, p = 0.027).ConclusionsWe found a sharp increase in the proportion of isolates that were resistant to moxifloxacin from 2007 to 2009. Further work needs to be done to characterize the nature of this increase.
- Published
- 2013